Clinical Trial Update: Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) [Phase 2]

View source ↗

Summary

A Phase 2 trial (ZENITH-CKD) evaluating the combination of zibotentan and dapagliflozin for chronic kidney disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• FARXIGA (dapagliflozin)
• Zibotentan (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-07-30